AstraZeneca Pharma India logo

AstraZeneca Pharma India financials: balance sheet, profit and loss, cash flow

NSE: ASTRAZENBSE: 506820Pharmaceuticals & BiotechnologySmall Cap

AstraZeneca Pharma India Limited · Formerly Astra IDL · Face value ₹2 · Listed Aug 1982 on BSE, May 2001 on NSE
Last close ₹6,237.00up ₹164.00 (2.70%)BSE ₹6,234.70

Share price at the NSE close on 28 Oct 2026. Previous close ₹6,073.00.

28 Oct: open ₹6,069.50, high ₹6,400.00, low ₹6,042.50

52-week range of traded prices to 28 Oct 2026
₹5,640.00Low, 9 Oct 2026₹9,849.50High, 3 Nov 2025
Market cap
₹15,593 Cr333rd largest listed
P/E
91.93
P/B
17.87
Dividend yield
0.58%
ROE
20.6%
ROCE
24.4%
Debt to equity
0.00
Volume, NSE
12,02539.4% delivered

AstraZeneca Pharma India's financial statements for the 10 years to Mar 2026, standalone: the listed company alone, without its subsidiaries, with the twelve months to Jun 2026 after them. It had no borrowings at 31 Mar 2026.

10 years at a glance

₹ crore, years to March.AstraZeneca Pharma India annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
54024Mar 1757226Mar 18728540Mar 19832720Mar 20814930Mar 21806620Mar 221,003990Mar 231,2961620Mar 241,7161160Mar 252,2761880Mar 26
Peak revenue ₹2,276 Cr, year to Mar 2026; lowest ₹540 Cr, year to Mar 2017

Operating and net margin, per cent

  • Operating margin
  • Net margin
16.7%4.5%9.8%14.5%16.7%10.7%16.5%14.2%14.8%11.5%4.5%4.5%7.5%8.7%11.5%7.6%9.9%12.5%6.7%8.2%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 2.1% of operating profit in the first full year.

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue2,276
  2. Materials and goods−1,381
  3. Employee costs−264
  4. Other expenses−369
  5. Operating profit262
  6. Depreciation−29
  7. Other income+28
  8. One-off items−5.3
  9. Finance costs−4.5
  10. Profit before tax252
  11. Tax−65
  12. Net profit188

What the company owns

  • Inventory₹1,027 Cr
  • Cash and bank₹449 Cr
  • Plant, investments and other assets₹299 Cr
  • Receivables₹214 Cr

What pays for it: net worth and liabilities

  • Net worth₹873 Cr
  • Owed to suppliers₹783 Cr
  • Other liabilities₹334 Cr

Profit and loss

Standalone, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.AstraZeneca Pharma India quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 26 MayJun 2026Twelve months
Revenue from operations5405727288328148061,0031,2961,7162,2762,432
––6577116787198381,1111,4622,0142,202
Materials and goods bought1741812313052953123605959631,3811,532
Employee costs––197217220230259241257264279
Other expenses––228189164177219275242369391
Operating profit before depreciation––7112113586165184254262230
Operating margin––9.8%14.5%16.7%10.7%16.5%14.2%14.8%11.5%9.5%
Materials, % of revenue––31.7%36.7%36.3%38.7%35.9%45.9%56.1%60.7%63.0%
Employee costs, % of revenue––27.1%26.1%27.0%28.6%25.8%18.6%15.0%11.6%11.5%
Other expenses, % of revenue––31.4%22.7%20.1%22.0%21.8%21.2%14.1%16.2%16.1%
Depreciation and amortisation1615151920171615402917
Operating profit after depreciation––5610211569149170214233213
Other income2012161313152635412826
Finance costs––011111146
Profit before one-off items and tax33447311412783174203253257233
One-off items––0000−4016−97−5−5
Profit before tax33447311412783134220156252228
918184234213558416559
Net profit24265472936299162116188170
Other comprehensive income––−1−53−2−31−1−4−5
Total comprehensive income––5467976097163115183164
Net margin4.5%4.5%7.5%8.7%11.5%7.6%9.9%12.5%6.7%8.2%7.0%
Operating expenses, operating profit before depreciation and operating profit after depreciation are left blank for the years to Mar 2017 and Mar 2018: the statement does not state its finance costs, which operating profit is worked out from, so operating profit is not given.
Earlier years, Mar 2011 to Mar 2016
₹ croreMar 201115 monthsMar 2012Mar 2013Mar 2014Mar 2015Mar 2016
Revenue from operations594532390474517564
––––––
Materials and goods bought130179153166200199
Depreciation and amortisation9–12–1517
Other income6610967
One-off items–––14––
Profit before tax10129−70–−216
Tax379191–1
Net profit6420−90−1−215
Net margin10.8%3.7%−22.9%−0.1%−4.0%0.9%
Standalone, ₹ crore, years to March.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 26 May
301364456511589712770873
Share capital55555555
Reserves296359451506584707765868
Borrowings00000000
259327303333384357703982
215151312945135
5627067758579851,0781,5181,989
1111151069998145176249
4515916697578879331,3421,732
Net debt−173−253−352−448−500−506−537−449
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 26 May
105101589365−15
1371269911713091
−433−30−128−103−218
Receivables−5−5−23−51−32−46
Inventories520−50−38−321−479
Payables−311037−31260326
Other working capital2796−8−11−20
Tax paid−33−25−41−56−64−83
Capital spending81091124
Free cash flow9791508264−19
173518223119
−9−9−24−44−66−92
Dividends paid5520406080
Shares bought back000000
Shares issued000000
Net change in cash26996527031−88
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Standalone, ₹ per share, years to March.AstraZeneca Pharma India dividend history

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 26 May
Earnings per share₹9.78₹10.37₹21.78₹28.88₹37.32₹24.64₹39.72₹64.60₹46.30₹75.01
Diluted earnings per share₹9.78₹10.37₹21.78₹28.88₹37.32₹24.64₹39.72₹64.60₹46.30–
Dividend per share–––₹1.00₹2.00₹10.00₹16.00₹24.00₹32.00₹36.00
Book value per share––₹120.32₹145.77₹182.47₹204.56₹235.48₹284.77₹308.14₹349.12
Dividend payout–––3.5%5.4%40.6%40.3%37.1%69.1%48.0%
Shareholder yield––––0.1%0.1%0.2%0.3%0.3%0.4%
Market cap at the year end (₹ crore)2,3382,3194,9726,0107,5236,3808,13213,32121,51919,414

Ratios

Standalone, years to March.AstraZeneca Pharma India PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 26 May
Revenue growth−4.3%6.0%27.3%14.2%−2.2%−1.0%24.5%29.2%32.5%32.6%
Operating profit growth–––69.3%12.2%−36.4%91.6%11.7%37.7%3.2%
Net profit growth364.8%6.0%110.1%32.6%29.2%−34.0%61.2%62.7%−28.3%62.0%
Earnings per share growth–6.0%110.0%32.6%29.2%−34.0%61.2%62.7%−28.3%62.0%
––18.1%21.7%22.7%12.7%18.1%24.8%15.6%22.8%
–––3.6 pts1.0 pts−10.0 pts5.3 pts6.8 pts−9.2 pts7.2 pts
From the net margin–––2.9 pts7.0 pts−7.6 pts3.8 pts4.7 pts−11.4 pts3.5 pts
From asset turnover–––0.3 pts−4.7 pts−1.5 pts1.7 pts3.5 pts0.7 pts−0.4 pts
From borrowing–––0.4 pts−1.3 pts−0.9 pts−0.1 pts−1.4 pts1.5 pts4.1 pts
Return on capital employed––18.7%28.0%25.3%13.5%25.3%23.8%27.8%26.7%
Cash conversion––––112.3%163.6%58.7%57.3%56.5%−8.1%
Interest cover–––89.8105.573.1235.1141.2146.652.0
Debt to equity––0.000.000.000.000.000.000.000.00
Receivable days––4037383939433934
Inventory days––187197198164193140208272
Payable days––266251221220231122173207
Cash conversion cycle, days––−39−1715−171617499
Working capital days––956−111202248
Asset turnover––1.301.311.100.991.091.261.321.30
Assets per rupee of net worth––1.871.911.801.691.671.591.752.13
Sales per rupee of plant––9.7311.6310.0510.8114.5621.4626.9919.37
Capital spending to depreciation––––0.380.570.520.720.040.13
Plant being built, % of plant in use––9.2%33.9%5.0%3.0%1.9%0.4%0.0%0.0%
No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
10.7%
Cash from operations against operating profit
−5.8%
Measure10 years5 years3 years
Revenue growth, yearly rate15.0%22.8%31.4%
Profit growth, yearly rate43.0%15.0%23.6%
Return on equity, average–18.8%21.1%
Return on capital employed, average–23.4%26.1%
Operating margin, average–13.5%13.5%
Net margin, average8.2%9.0%9.2%
Asset turnover, average–1.191.29
Cash conversion cycle, days, average–4478
Interest cover, average–129.6113.2
Debt to equity, average–0.000.00

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations302143−15
Cash from investing947119
Cash from financing−236−202−92
Capital spending34164
Dividends paid20518080
Shares bought back000
Shares issued for cash000
Borrowings raised000
Borrowings repaid000

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––757643
Altman Z-scorePublished threshold 1.81––14.3013.4217.1513.7815.2325.2719.9513.07
Beneish M-scorePublished threshold −1.78––––−2.66−2.71−2.07−1.65−1.54−1.69
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––−24.92−5.392.494.581.5110.49
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––1.040.780.570.31
Receivables growth less revenue growthOur threshold 0 percentage points–––−9.874.571.800.6913.24−11.74−17.01
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––7.770.13−18.0220.26−45.3678.7243.94
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––1.24−2.251.420.62−3.321.53−1.29
Assets under construction, years of additionsOur threshold 2 years of additions–––1.590.140.210.130.040.000.00
Effective tax ratePublished threshold 17.16 per cent26.3940.8325.0836.6426.5925.8225.9626.4325.9825.65
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––−4.04−4.480.73−15.07−7.39
A threshold marked as ours has no published figure; it is the line we read the check against.